Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 · Nature Reviews Clinical Oncology · 2,279 citations
https://doi.org/10.1038/nrclinonc.2017.148
W
William G. Wierda
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.5K
Papers
62.3K
Citations
121
h-index
583
i10-index
William G. Wierda is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Chronic Myeloid Leukemia Treatments. The author has an h-index of 121, co-authored 1300 publications.
ORCID: 0000-0002-7357-270XPapers by this author
worksUse of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
2020 · New England Journal of Medicine · 2,002 citations
https://doi.org/10.1056/nejmoa1910607
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
2021 · The Lancet · 721 citations
https://doi.org/10.1016/s0140-6736(21)01222-8
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
2018 · The Lancet Oncology · 238 citations
https://doi.org/10.1016/s1470-2045(18)30011-1
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
2022 · Leukemia · 194 citations
https://doi.org/10.1038/s41375-021-01485-x
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
2010 · Blood · 107 citations
https://doi.org/10.1182/blood-2010-01-262808
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat